Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239135 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
A Phase 2 study, sponsored by Peplin.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00239135 is a Phase 2 study that has completed, run by Peplin. The registered enrollment target is 34 participants.
The verdict
NCT00239135, a Phase 2 study, has completed, sponsored by Peplin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is : * To determine the maximum tolerated dose (MTD) for PEP005 Topical Gel in patients with actinic keratoses. * To evaluate patients for clinical safety * To determine the systemic absorption of PEP005 Topical Gel
Interventions
- DRUG PEP005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2005-09 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239135
The ClinicalTrials.gov registry entry for NCT00239135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peplin, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PEP005 is the first listed.
NCT00239135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239135 about?
NCT00239135 is a clinical study titled "Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel". The purpose of this study is : * To determine the maximum tolerated dose (MTD) for PEP005 Topical Gel in patients with actinic keratoses. * To evaluate patients for clinical safety * To determine the systemic absorption of PEP005 Topical Gel
What is the current status of trial NCT00239135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2005-09. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00239135?
The interventions under investigation include: PEP005 (DRUG).
Who is sponsoring clinical trial NCT00239135?
This trial is sponsored by Peplin, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.